spacer
home > ict > autumn 2017 > expert knowledge
PUBLICATIONS
International Clinical Trials

Expert Knowledge

After the US and Europe, Japan is the most important
market for biopharmaceutical R&D companies. The
Japanese pharmaceutical industry is worth $81 billion
and the major global companies have well-established
marketing and R&D operations in the region. Demands
for effective pharma products in Japan are growing,
but the current government emphasis on reducing
rising healthcare expenditure in the face of a rapidly
ageing population has made the business environment
challenging for the industry.

Japan has a mature, developed pharma market that is very
sensitive with respect to research quality, as the medical
community is exclusive, hierarchical and conservative.
Only 34% of clinical research is conducted by non-Japanese
businesses. During the late 1990s, several global CROs
expanded their operations, setting up offices in Japan to
coordinate global multicentre clinical trials as a part of their
drug development support to multinational companies.
In doing so, they have adapted to the different clinical
research environment in Japan, which is more resource-
focused and, therefore, more expensive when compared to
clinical trials in other regions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mary Pan is Vice President of General Management and Business Development at ICON, Asia Pacific, where she is responsible for growing and enhancing ICON’s presence in the region. She has over 17 years of global pharma and clinical development expertise, with a strong track record in Asia through roles at Becton Dickinson, ClinTec International, Johnson & Johnson and Pfizer. Mary holds bachelor degrees in economics and psychology and a Master of Business Administration from Brown University, US, and also has a law degree from the University of Edinburgh, UK.
spacer
Mary Pan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Gyros Protein Technologies Appoints Frank Witney as Chairman

Automated nanoliter-scale immunoassays company today announced the appointment of a new Chairman of the Board
More info >>

White Papers

pAVEway™ expression system for the efficient expression of therapeutic proteins

Fujifilm Diosynth Biotechnologies

One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells. The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).
More info >>

 
Industry Events

Cell Therapy Manufacturing & Gene Therapy Congress

6-7 December 2017, RAI, Amsterdam

Bringing together 300+ leaders and key influencers from pharma and biotech companies on 6 - 7 December 2017 in Amsterdam, Cell Therapy Manufacturing & Gene Therapy Congress will provide you with the latest advice for driving manufacturing and commercialisation through direct access to transforming innovative research to prosperous cell & gene manufacturing.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement